This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
All eligible patients who presented to the Hypertension Unit of the Department of Emergency Medicine in the General Hospital of Vienna between January 1999 and July 2001 were enrolled in the study, after informed consent had been obtained. No power calculations, to determine or assess the sample size, were performed either prospectively or retrospectively. There was also no evidence that the sample size was appropriate for the clinical study.
A total of 152 patients (77 men and 75 women) were enrolled. The median age of the patients was 60 years (25th to 75th interquartile range, IQR: 55 -70). Laboratory values for renal function and serum electrolytes were within the normal range for all patients. The median body mass index was 28 (IQR: 25 -31). The median duration of hypertension was 5 years (IQR: 1 -10). The median clinical systolic BP was 150 mmHg (IQR: 140 -161) and the median clinical diastolic BP was 87 mmHg (IQR: 81 -92). The median values for ambulatory BP were 139 mmHg (IQR: 130 -144) systolic and 81 mmHg (IQR: 74 -88) diastolic. It was not reported that any patients refused to participate, or were excluded from the initial sample.
Study design
This was a diagnostic cross-sectional study that was conducted in one hospital. The patients were screened for diabetes using a combination of screening tests, and then a 'gold' standard method was used to determine the diagnosis of diabetes. The follow-up lasted until the point at which the final diagnosis was confirmed (probably from a few hours to a few days). There were no losses to follow-up.
Analysis of effectiveness
All the patients included in the study were accounted for in the analysis. The primary outcomes measured were the test characteristics of the screening methods evaluated (i.e. sensitivity, specificity, positive predictive value and negative predictive value). For the fasting PG test, the results were considered positive if the fasting PG was 7.0 mmol/L. The sensitivity and specificity of the HbA1c test to diagnose diabetes (i.e. predict a 2-hour PG of 11.1 mmol/L) were examined by receiver operating characteristic curve (ROC) analysis. The performance of HbA1c to diagnose diabetes was expressed as the area under the curve.
As the study involved only a single group of patients, comparability of the groups and adjustments for confounding factors were not an issue. However, the authors showed that, within the group, patients with a diagnosis of diabetes and those without such a diagnosis did not differ in age, body mass index, duration of hypertension, or systolic and diastolic DBP (both clinical and ambulatory). The only statistically significant difference was found in family history of diabetes mellitus, (p=0.019), where 29% of patients with a diagnosis of diabetes had a family history of diabetes versus 12% of those with no diabetes diagnosed.
Effectiveness results
Diabetes was diagnosed in 33 of the 152 patients (22%) by performing an OGTT (gold standard method).
For the stepwise approach, in the first step of screening all patients for fasting PG, 25 patients (16% of all patients, or 76% of diabetic patients) were identified as diabetic (all true positive).
Eight out of 152 patients would be falsely classified as nondiabetic individuals.
In the remaining 127 patients, HbA1c was measured to identify additional diabetic cases.
The cut-off for HbA1c, as determined by ROC analysis, was 6.1%.
The area under the curve was 0.87 (95% confidence interval: 0.79 -0.95).
The identified cut-off of 6.1% revealed a sensitivity of 100% and a specificity of 75%.
The combined use of fasting PG and HbA1c identified all diabetic patients and revealed no false negative results (but it led to a number of false positive results).
The HbA1c test resulted in 38 patients being classified as positive. These were subsequently re-tested with OGTT to identify the true positive patients.
Clinical conclusions
The combination of fasting PG and HbA1c was a reasonable alternative to the generally recommended OGTT for the screening of diabetes in hypertensive patients, as diabetes was correctly diagnosed in all patients by this stepwise procedure and the number of confirmatory OGTTs required was reduced.
Measure of benefits used in the economic analysis
The benefit used in the economic analysis was the number of diabetic patients that were diagnosed either by the stepwise procedure or the comparator, out of the total number of patients screened. However, since the stepwise procedure was designed in such a way that all diabetic patients were ultimately diagnosed (100%), and as this was also the case with the 'gold' standard procedure that served as the comparator, the economic analysis was conducted in a manner that only considered the costs.
Direct costs
The study perspective was that of a hospital. The costs consisted of those for screening only, for the identification of all patients with diabetes. The costs included were for physicians, nurses and laboratory procedures. The costs and the quantities were not reported separately. The costs were obtained from the finance department of the hospital in which the study took place. The total costs were estimated from actual data (i.e. the number of screening tests needed in the population examined) for the identification of all diabetes cases. Discounting was not carried out, which was appropriate since the costs were incurred during less than one year. The date to which the prices referred was not reported.
Statistical analysis of costs
The costs were treated deterministically. No statistical analysis of the costs was performed.
Indirect Costs
The indirect costs were not included in the analysis.
Currency
The costs were expressed in both Euros (Euro) and US dollars ($). The conversion rate was not reported.
Sensitivity analysis
No sensitivity analysis was performed.
Estimated benefits used in the economic analysis
The benefit used in the economic analysis was the number of diabetic patients diagnosed either by the stepwise procedure or the comparator, out of the total number of patients screened. The stepwise procedure was designed in such a way that all patients with diabetes were ultimately diagnosed from the study sample (33 of the 152 patients participating in the study (22%); 33 of the 33 diabetes cases within the study sample (100%)). The standard procedure also revealed all 33 diabetes cases.
Cost results
The total cost of the stepwise screening procedure (152 fasting PG, 127 HbA1c, and 38 OGTT) was $6,436.90 (Euro 6,569.54).
